Treating_Aids-_The_Global_Ethical_Dilema

Treating Aids- The Global Ethical Dilema Treating AIDS—The Global Ethical Dilemma Statistics show that ninety percent of the world’s 33 million HIV/AIDS cases are in Africa, Latin America, and Asia. These areas are known to be much more deficient and therefore can not afford the drug to help fight AIDS. The quandary for the drug companies is how to make these drugs more inexpensive. These drugs are very much needed. 8 percent of the 38 million people in South Africa are infected with the AIDS virus. Western drug companies face issues of social responsibility in both short and long terms. Their short term responsibility is to deal with the pressure they are receiving from health organizations around the world, global competition, compassion for those unfortunate that can’t be treated, and to maintain a benevolent image. The long term responsibility the industry is faced with is maintaining sufficient revenue to support the goal of developing a cure for AIDS and other diseases. Along with getting the drug to everyone in need, the pharmaceutical industry is fighting to protect the patents on their drugs. Large companies are in business to invest numerous amounts of money to develop drugs. Patents drug, drugs, companies, aids, south, african, world, patents, government, countries, without, responsibility, percent, law, industry, term, should, short, protect, prices, pressure, pharmaceutical, per, people, much, million, long, local, image, health, global, generic, dropped, doctors, developing